NIMODIPINE AND MEMANTINE FOR THE NEUROLOGICAL MANIFESTATIONS OF HIV-1
尼莫地平和美金刚治疗 HIV-1 的神经表现
基本信息
- 批准号:6112478
- 负责人:
- 金额:$ 27.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-05-01 至 2000-04-30
- 项目状态:已结题
- 来源:
- 关键词:2'3' dideoxyinosine AIDS dementia complex AIDS therapy NMDA receptors calcium channel blockers clinical trials combination chemotherapy drug adverse effect drug screening /evaluation human subject human therapy evaluation inhibitor /antagonist macrophage membrane channels nervous system disorder chemotherapy neurologic manifestations neuropsychological tests zidovudine
项目摘要
The neurological manifestations of HIV-1 affect between one and two-
thirds of adults patients with AIDS. Included in these complications are
a form of dementia producing cognitive, motor, and possible visual
dysfunction in the absences of viral infection of neurons, in the absence
of opportunistic superinfections, and in the absence of HIV-associated
malignancies of the CNS. Recent progress has been made in the laboratory
investigation of the basis for this form of dementia (termed the AIDS
dementia complex, or more recently, HIV-associated motor/cognitive
complex). Evidence from a variety of laboratories around the world
suggests that at least part of the neuronal loss observed in the brains
of patients with AIDS may be related to a final common pathway invoking
excessive stimulation of excitatory amino acid receptors such as the N-
methyl-D-aspartate (NMDA)subtype of these receptors. These findings are
in the mainstream of current neuroscience research which has found that
several acute and degenerative neurologic disorders, ranging from stroke
to trauma and epilepsy to Huntington's disease, may have a similar basis
for neuronal injury. In the face of overstimulation of excitatory amino
acid receptors, ion channels permit excessive influx of calcium ions and
consequent nerve cell injury. Although the exact mechanism for neuronal
injury by calcium overload is still a matter of intense investigation and
current debate, many laboratories have found that limiting the influx of
calcium ions under these conditions can protect neurons form injury. For
example, laboratory investigation using in vitro and in vivo animal
models has suggested that blockade of ion channels permeable to calcium
ions may prevent nerve cell damage engendered by HIV-infected macrophages
or macrophages stimulated by the HIV-1 coat protein, gp120. At least two
types of ion channels contribute to this form of injury, L-type voltage-
dependent calcium channels and NMDA receptor-coupled channels. For this
reason, clinically-tolerated antagonists of these channels are proposed
to be studied in conjunction with the best available anti-retroviral
therapy, i.e. zidovudine (ZDV) or nucleosides such as dideoxyinosine
(ddI). A second study will be used an adjunctive therapy to these anti-
retroviral another well-known drug, memantine, which has recently been
recognized to be a potent NMDA open-channel blocker capable of
attenuating neuronal injury associated with exposure to gp120 by the
P.I.'s laboratory.
HIV-1的神经学表现在一到两个之间-
三分之一的成人艾滋病患者。这些并发症包括
一种痴呆症,产生认知、运动和可能的视觉
在没有病毒感染的神经元中的功能障碍
机会性双重感染,在没有艾滋病毒相关的情况下
中枢神经系统的恶性肿瘤。最近在实验室里取得了进展
对这种类型痴呆(称为艾滋病)的基础的调查
痴呆症,或最近的HIV相关运动/认知
复杂)。来自世界各地不同实验室的证据
这表明在大脑中观察到的神经元丢失的至少一部分
可能与艾滋病患者的最终共同途径有关
过度刺激兴奋性氨基酸受体,如N-
这些受体的甲基-D-天冬氨酸(NMDA)亚型。这些发现是
在当前神经科学研究的主流中,已经发现
几种急性和退行性神经疾病,从中风
对创伤和癫痫到亨廷顿病,可能有类似的基础
用于神经元损伤。面对兴奋性氨基酸的过度刺激
酸性受体,离子通道允许钙离子过度内流和
继而导致神经细胞损伤。尽管神经元的确切机制
钙超载造成的损伤仍在紧张调查中
目前的争论中,许多实验室都发现限制细菌的涌入
在这些条件下,钙离子可以保护神经元免受损伤。为
例如,使用体外和活体动物进行的实验室调查
模型表明,阻断钙离子通道可以渗透到钙离子
离子可能防止HIV感染的巨噬细胞引起的神经细胞损伤
或由HIV-1外壳蛋白gp120刺激的巨噬细胞。至少两个
离子通道的类型促成了这种形式的损伤,L型电压-
依赖性钙通道和NMDA受体偶联通道。为了这个
提出了临床可耐受的这些通道拮抗剂的原因
与现有最好的抗逆转录病毒药物一起进行研究
治疗,即齐多夫定(ZDV)或核苷,如双脱氧肌苷
(DDI)。第二项研究将用于这些抗癌药物的辅助治疗。
逆转录病毒另一种著名的药物美金刚,最近被
公认为一种有效的NMDA开放通道阻滞剂,能够
减轻暴露于gp120所致的神经元损伤
P.I.S实验室。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART A LIPTON其他文献
STUART A LIPTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART A LIPTON', 18)}}的其他基金
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
阿尔茨海默病中先天免疫人类小胶质细胞和适应性免疫 Tregs 之间的串扰
- 批准号:
10686979 - 财政年份:2022
- 资助金额:
$ 27.36万 - 项目类别:
Crosstalk between innate-immunity human microglia and adaptive-immunity Tregs in Alzheimer's disease
阿尔茨海默病中先天免疫人类小胶质细胞和适应性免疫 Tregs 之间的串扰
- 批准号:
10515987 - 财政年份:2022
- 资助金额:
$ 27.36万 - 项目类别:
Pro-Electrophilic Drugs PEDs for Alzheimer's Disease
用于治疗阿尔茨海默病的亲电药物 PED
- 批准号:
10230417 - 财政年份:2020
- 资助金额:
$ 27.36万 - 项目类别:
Pro-Electrophilic Drugs PEDs for Alzheimer's Disease
用于治疗阿尔茨海默病的亲电药物 PED
- 批准号:
10256731 - 财政年份:2020
- 资助金额:
$ 27.36万 - 项目类别:
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's Disease
散发性阿尔茨海默病中 S-亚硝基化诱导的翻译后修饰和异常细胞信号转导
- 批准号:
9919542 - 财政年份:2017
- 资助金额:
$ 27.36万 - 项目类别:
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's Disease
散发性阿尔茨海默病中 S-亚硝基化诱导的翻译后修饰和异常细胞信号转导
- 批准号:
9355868 - 财政年份:2017
- 资助金额:
$ 27.36万 - 项目类别:
Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse
治疗 HIV 相关神经认知障碍的蛋白质组学新方法
- 批准号:
9884749 - 财政年份:2016
- 资助金额:
$ 27.36万 - 项目类别:
相似海外基金
The kynurenine pathway chemokines and MIC-1 in the pathogenesis of AIDS dementia complex.
犬尿氨酸途径趋化因子和 MIC-1 在艾滋病痴呆复合体发病机制中的作用
- 批准号:
nhmrc : 209548 - 财政年份:2002
- 资助金额:
$ 27.36万 - 项目类别:
NHMRC Project Grants
MRS OF PATS W/ AIDS DEMENTIA COMPLEX: MULTICENTER ACTG 301 DRUG EVAL PROGRAM
患有艾滋病痴呆症的 PATS 夫人:多中心 ACTG 301 药物评估计划
- 批准号:
6657668 - 财政年份:2002
- 资助金额:
$ 27.36万 - 项目类别:
ACTG 301 TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX (ADC)
ACTG 301 美金刚治疗艾滋病痴呆症 (ADC) 的试验
- 批准号:
6571869 - 财政年份:2002
- 资助金额:
$ 27.36万 - 项目类别:
NEUROLOGICAL EVALUATION OF THE AIDS DEMENTIA COMPLEX IN ACTG CLINICAL TRIALS
ACTG 临床试验中艾滋病痴呆症的神经学评估
- 批准号:
6445211 - 财政年份:2001
- 资助金额:
$ 27.36万 - 项目类别:
MRS OF PATS W/ AIDS DEMENTIA COMPLEX: MULTICENTER ACTG 301 DRUG EVAL PROGRAM
患有艾滋病痴呆症的 PATS 夫人:多中心 ACTG 301 药物评估计划
- 批准号:
6495477 - 财政年份:2001
- 资助金额:
$ 27.36万 - 项目类别:
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY
ACTG 301--美金刚联合抗逆转录病毒疗法治疗艾滋病痴呆症
- 批准号:
6565844 - 财政年份:2001
- 资助金额:
$ 27.36万 - 项目类别:
NEUROLOGICAL EVALUATION OF THE AIDS DEMENTIA COMPLEX IN ACTG CLINICAL TRIALS
ACTG 临床试验中艾滋病痴呆症的神经学评估
- 批准号:
6302834 - 财政年份:2000
- 资助金额:
$ 27.36万 - 项目类别:
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY
ACTG 301--美金刚联合抗逆转录病毒疗法治疗艾滋病痴呆症
- 批准号:
6468094 - 财政年份:2000
- 资助金额:
$ 27.36万 - 项目类别:
ROLE OF KUNURENINE PATHWAY METABOLITES IN THE PATHOGEN-ESIS OF THE AIDS DEMENTIA COMPLEX
昆仑氨酸途径代谢物在艾滋病痴呆症发病中的作用
- 批准号:
nhmrc : 7484 - 财政年份:2000
- 资助金额:
$ 27.36万 - 项目类别:
CARG - People
PHASE II TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX (ACTG301)
美金刚治疗艾滋病痴呆症的二期试验 (ACTG301)
- 批准号:
6568641 - 财政年份:2000
- 资助金额:
$ 27.36万 - 项目类别:














{{item.name}}会员




